“We are very happy to establish an R&D lab in AstraZeneca’s BioVentureHub. It gives us a unique opportunity to collocate with, and tap into, the power of AstraZeneca’s world-class scientists and facilities, as well as with the other exciting life science companies in the hub. Surrounded by experts in cardiovascular, metabolic, respiratory and oncology diseases, it’s a truly inspiring environment in which to develop our future offering of bioprinting technologies.” Erik Gatenholm, (co-founder and CEO, CELLINK)
Located in the BioVentureHub, at the heart of AstraZeneca’s R&D Gothenburg site, the new lab will be staffed by a team of four scientists and researchers. They will focus on developing opportunities for customers and partners to bioprint using any type of cells relevant to the targeted applications.
The BioVentureHub continues to grow. With CELLINK onboard, and after 8 new companies joined in 2017, there are currently 25 companies and 1 academic group in the BioVentureHub.
“CELLINK is developing exciting 3D bioprinting technologies that are enabling new ways to study biological systems and develop better treatments. Delivering on our ambition to facilitate interactions between drug, device, diagnostic and digital health companies, Erik and the CELLINK team will undoubtedly add significant value to the innovation experiment we are building here at the BioVentureHub.” Magnus Björsne, (CEO, AstraZeneca BioVentureHub)
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with – and tap into – the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other.